Journal of Diabetes最新文献

{"title":"Prevalence and Severity of Coronary Artery Calcification Assessed by Low-Dose Computed Tomography in Individuals With Type 2 Diabetes With and Without Diabetic Foot: A Cross-Sectional Study","authors":"Feiyan Shi,&nbsp;Yun Gao,&nbsp;Mingxin Bai,&nbsp;Ruixue Feng,&nbsp;Chunjie Ma,&nbsp;Dawei Chen,&nbsp;Chun Wang,&nbsp;Lihong Chen,&nbsp;Sen He,&nbsp;Donge Yan,&nbsp;Chunchao Xia,&nbsp;Xingwu Ran","doi":"10.1111/1753-0407.70247","DOIUrl":"10.1111/1753-0407.70247","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To investigate whether diabetic foot (DF) is associated with a higher prevalence and severity of coronary artery calcification (CAC) in patients with type 2 diabetes (T2DM) using low-dose computed tomography (LDCT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study included 710 patients with DF and 1176 patients with T2DM but without DF who had undergone LDCT recruited in the Diabetic Foot Care Center of West China Hospital, Sichuan University. The severity of CAC was evaluated using a length-based grading method. The independent association between DF and CAC was evaluated using multivariable logistic regression and propensity score matching (PSM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The overall prevalence of CAC among individuals with DF was 71.9%, compared to 46.1% in those without DF. DF was independently associated with CAC; an association remained statistically significant after PSM (adjusted OR 1.72; 95% CI [1.28–2.32]; <i>p</i> &lt; 0.001). This association was particularly strong in patients with preserved renal function, irrespective of the presence of peripheral artery disease (PAD). In contrast, among individuals with impaired renal function, no significant differences were observed in the prevalence of mild, moderate, or severe CAC between those with DF and those without DF. However, the overall prevalence of CAC across all severity levels was higher in the renal-impaired group than in those with preserved renal function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>DF is independently associated with the presence and severity of CAC in patients with T2DM, particularly among those with preserved renal function, irrespective of the presence of concomitant PAD. This association is not statistically significant in individuals with impaired renal function.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70247","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148262418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pityriasis Lichenoides et Varioliformis Acuta Associated With Tirzepatide: A First Report","authors":"Muzaffer Serdar Deniz,&nbsp;Gulhan Aksoy Sarac,&nbsp;Burak Celik,&nbsp;Merve Kaya,&nbsp;Hilal Balta,&nbsp;Muzeyyen Kecik,&nbsp;Oya Topaloglu,&nbsp;Reyhan Ersoy,&nbsp;Bekir Cakir","doi":"10.1111/1753-0407.70233","DOIUrl":"10.1111/1753-0407.70233","url":null,"abstract":"&lt;p&gt;Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated substantial efficacy in glycemic control and weight reduction in type 2 diabetes mellitus and obesity. Its overall safety profile is favorable, with gastrointestinal symptoms and injection-site reactions representing the most commonly reported adverse events [&lt;span&gt;1&lt;/span&gt;]. However, rare immune-mediated dermatologic reactions continue to emerge with broader clinical use. We report, to our knowledge, the first case of pityriasis lichenoides et varioliformis acuta (PLEVA) temporally associated with tirzepatide therapy.&lt;/p&gt;&lt;p&gt;A 41-year-old man with type 2 diabetes mellitus (HbA1c 6.8%, BMI 30.5 kg/m&lt;sup&gt;2&lt;/sup&gt;) developed a localized cutaneous eruption 5 days after his second weekly tirzepatide dose. He denied recent infections, systemic symptoms, or exposure to new medications aside from tirzepatide. Physical examination revealed clustered erythematous, mildly scaly papules on the right lateral tibial region, the largest measuring approximately 6–8 mm in diameter with a central hemorrhagic crust. There was no mucosal involvement, lymphadenopathy, or systemic findings. Laboratory evaluations, including complete blood count, complete metabolic panel, and lipid profile, were unremarkable except for an elevated fasting glucose of 127 mg/dL. Of note, lesions were confined to the right leg; while unusual, localized presentations of PLEVA have been documented.&lt;/p&gt;&lt;p&gt;Punch biopsy demonstrated mild spongiosis and acanthosis, minimal vacuolar degeneration of the basal layer, intraepidermal lymphocytic exocytosis, scattered neutrophilic debris, erythrocyte extravasation, and perivascular and lichenoid lymphocytic infiltration with melanophages in the dermis (Figure 1). Perivascular and periadnexal lymphocytic infiltration was also observed in the deep dermis (Figure 2). These findings argued against guttate psoriasis and lichen planus and were consistent with PLEVA [&lt;span&gt;2&lt;/span&gt;]. Pityriasis rosea was excluded by the absence of a herald patch, and syphilis serology was negative. Lymphomatoid papulosis remained the closest histopathological mimicker; CD30 immunostaining and the clinical course are typically used to distinguish between them, though immunohistochemistry was not performed in this case. Following dermatological consultation, the patient opted to discontinue tirzepatide.&lt;/p&gt;&lt;p&gt;Drug-induced PLEVA is rare but documented with several medications, including antibiotics (e.g., penicillins and macrolides), vaccines, and immunomodulatory therapies such as tumor necrosis factor inhibitors, though causality often remains uncertain [&lt;span&gt;3&lt;/span&gt;]. GLP-1 receptor agonists have been increasingly associated with immune-mediated dermatologic conditions, including bullous pemphigoid, eosinophilic panniculitis, morbilliform eruptions, and lichen planus pigmentosus [&lt;span&gt;4, 5&lt;/span&gt;]. The pathogenesis of PLEVA invol","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2026-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148262482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing the Development of the China-SCO Cooperation Center for Metabolic Diseases to Foster a Global Community of Health for All","authors":"Guang Ning","doi":"10.1111/1753-0407.70244","DOIUrl":"https://doi.org/10.1111/1753-0407.70244","url":null,"abstract":"&lt;p&gt;At present, metabolic diseases have become a major global public health challenge threatening human health. They not only impose a substantial disease burden on patients and their families, but also present severe challenges to healthcare systems as well as socioeconomic development worldwide.&lt;/p&gt;&lt;p&gt;President Xi Jinping has emphasized the importance of advancing a more just and equitable global governance system and working together toward the building of a global community with a shared future for mankind. At the 24th Meeting of the Council of Heads of Government (Prime Ministers) of the Shanghai Cooperation Organization (SCO) Member States held in Moscow, Premier Li Qiang formally proposed the establishment of the China-SCO Cooperation Center for Metabolic Diseases. The initiative received positive responses and broad support from all member states. This initiative fully demonstrates China's sense of responsibility as a major country and opens up broad new prospects for health cooperation within the SCO.&lt;/p&gt;&lt;p&gt;Three months ago, the China-SCO Cooperation Center for Metabolic Diseases was officially inaugurated in Shanghai. Mayor Gong Zheng and SCO Secretary-General Yermekbayev jointly unveiled the Center, marking a solid step forward in healthcare cooperation within the SCO. Guided by the principles of multi-level integration, network-based collaboration, and intelligent development, the Center is committed to establishing four major platforms. First, an international medical service platform to provide high-quality and efficient diagnosis and treatment services for metabolic diseases; second, a dual-track precision talent training platform to cultivate professional teams for disease prevention, control, and management; third, a strategic disease research platform to advance high-level scientific research and innovation; and fourth, a pharmaceutical and medical technology cooperation platform to promote technological innovation and the sharing of achievements.&lt;/p&gt;&lt;p&gt;To achieve these goals, I would like to propose the following six initiatives:&lt;/p&gt;&lt;p&gt;First, medical training centers should be established across member states to develop a regional talent cultivation system for metabolic diseases and related disorders. These medical training centers will operate under the guidance of the Academic Committee of the China-SCO Cooperation Center for Metabolic Diseases. Drawing upon the successful experience of the National Metabolic Management Center (MMC) model, the centers will design and develop structured training curricula. At the same time, the programs will be locally adapted to meet the needs of the healthcare systems of different countries, thereby creating an innovative training framework to cultivate specialized professionals in metabolic disease management for all member states.&lt;/p&gt;&lt;p&gt;Second, the establishment of MMCs should be promoted across member states to help improve the regional capacity for the diagnosis and treatment of metabolic","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70244","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148209077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Sodium-Glucose Cotransporter 2 Inhibitors Treatment With Contrast-Induced Acute Kidney Injury in Older Adults With T2D and CKD: A Propensity Matched Analysis","authors":"Jing Ma,&nbsp;Qing Yang,&nbsp;Xing Yang,&nbsp;Ke Liu,&nbsp;Xiaolei Chen,&nbsp;Fang Liu","doi":"10.1111/1753-0407.70243","DOIUrl":"https://doi.org/10.1111/1753-0407.70243","url":null,"abstract":"&lt;p&gt;Contrast-induced acute kidney injury (CI-AKI) is responsible for the third highest proportion of hospital-acquired AKI and has been linked with increased risks of chronic kidney disease (CKD) progression, in-hospital dialysis, and mortality [&lt;span&gt;1, 2&lt;/span&gt;]. Older age, type 2 diabetes (T2D), and pre-existing CKD markedly elevate the risk of CI-AKI [&lt;span&gt;3-6&lt;/span&gt;]; however, targeted pharmacological preventive strategies remain limited [&lt;span&gt;7&lt;/span&gt;]. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) hold promise for preventing CI-AKI [&lt;span&gt;8-10&lt;/span&gt;], but their renoprotective effects in older, high-risk adults with T2D and advanced CKD remain uncertain, as most previous trials enrolled patients with early-stage CKD [&lt;span&gt;11&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;This retrospective analysis included adults receiving coronary angiography (CAG) or percutaneous coronary intervention (PCI) at West China Hospital of Sichuan University between February 2020 and February 2025. We identified 491 older adults (≥ 60 years) with T2D and CKD who had pre- and post-procedure serum creatinine (Scr) measurements (Figure S1). The primary outcome was the in-hospital incidence of CI-AKI, defined by the European Society of Urogenital Radiology (ESUR) criteria (CI-AKI&lt;sub&gt;ESUR&lt;/sub&gt;), with the KDIGO Scr criteria (CI-AKI&lt;sub&gt;KDIGO&lt;/sub&gt;) used for sensitivity analysis [&lt;span&gt;12, 13&lt;/span&gt;]. Participants were categorized as SGLT2-Is users or nonusers based on their admission medication status. To balance baseline characteristics, SGLT2-Is users were 1:1 matched to nonusers using propensity score matching (PSM).&lt;/p&gt;&lt;p&gt;The 491 participants had an average age of 75.5 years, 61% were male, and the mean estimated glomerular filtration rate (eGFR) was 41.9 mL/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;. The overall in-hospital incidence of CI-AKI was 18% (Table S1). After PSM, 111 SGLT2-Is users were matched to 111 nonusers, and baseline characteristics were well-balanced between the two groups. Among SGLT2-Is users, 94.6% were treated with dapagliflozin and 5.4% with empagliflozin (Table S2). In the matched cohort, SGLT2-Is users had a significantly lower risk of CI-AKI. The incidence of CI-AKI&lt;sub&gt;ESUR&lt;/sub&gt; was 9.9% in the SGLT2-Is group compared with 26% in the nonusers' group (&lt;i&gt;p&lt;/i&gt; = 0.003). The unadjusted odds ratio (OR) for CI-AKI&lt;sub&gt;ESUR&lt;/sub&gt; was 0.33 (95% CI: 0.15–0.68; &lt;i&gt;p&lt;/i&gt; = 0.004), and the adjusted OR was 0.31 (95% CI: 0.14–0.66; &lt;i&gt;p&lt;/i&gt; = 0.003) after adjusting for age, sex, HbA1c, and high-density lipoprotein (HDL). Notably, this risk reduction was more pronounced with dapagliflozin treatment (aOR: 0.26 for CI-AKIESUR, 95% CI: 0.11–0.56, &lt;i&gt;p&lt;/i&gt; = 0.001). This protective association was consistent when CI-AKI was redefined using the KDIGO criteria (aOR: 0.41, 95% CI: 0.18–0.90; &lt;i&gt;p&lt;/i&gt; = 0.03) (Figure 1).&lt;/p&gt;&lt;p&gt;In secondary analyses, post-procedural Scr was numerically higher in nonusers, though no significant intergroup difference was observed (Table S3). Multivariate analysis","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70243","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148209016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148075044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Implications of the 2025–2030 Dietary Guidelines for Americans for Diabetes and Prediabetes Management","authors":"Yoriko Heianza,&nbsp;Frank B. Hu","doi":"10.1111/1753-0407.70234","DOIUrl":"10.1111/1753-0407.70234","url":null,"abstract":"&lt;p&gt;Lifestyle changes, including dietary modifications, can reduce the risk of developing type 2 diabetes by approximately 40%–50% in high-risk adults with prediabetes [&lt;span&gt;1&lt;/span&gt;]. Individualized medical nutrition therapy (MNT) is an essential component of diabetes management and is associated with significant reductions in HbA1c levels in individuals with type 1 or type 2 diabetes [&lt;span&gt;2&lt;/span&gt;]. The 2025–2030 Dietary Guidelines for Americans (DGAs), issued by the U.S. Department of Health and Human Services and the U.S. Department of Agriculture [&lt;span&gt;3&lt;/span&gt;], provide updated recommendations emphasizing diets built on whole, nutrient-dense “real foods.” These include high-quality protein at every meal from a variety of animal and plant sources, healthy fats, colorful vegetables and fruits, and whole grains. The new DGAs also call for a substantial reduction in highly processed foods rich in refined carbohydrates, added sugars, excess sodium, unhealthy fats, and additives [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Although developed primarily for U.S. nutrition programs such as school meals, the DGAs also influence clinical nutrition practice more broadly. In this commentary, we discuss the potential implications of these recommendations for diabetes management and prevention, as well as the challenges and considerations involved in their implementation. We also discuss whether the new DGAs align with the American Diabetes Association (ADA) Standards of Care Nutrition Recommendations [&lt;span&gt;2&lt;/span&gt;]. As summarized in Table 1, the core components of the 2025–2030 DGAs align broadly with the ADA MNT principles, particularly regarding whole foods, fiber-rich carbohydrates, and reduced added sugars. However, certain recommendations, especially those related to animal-derived saturated fats and elevated protein targets, are not fully aligned with cardiovascular and kidney risk considerations, especially in high-risk individuals.&lt;/p&gt;&lt;p&gt;The new DGAs explicitly emphasize limiting highly processed foods, added sugars, refined carbohydrates, and sugar-sweetened beverages (Table 1). They also recommend restricting sodium intake to less than 2300 mg/day and limiting saturated fat to less than 10% of total daily calories. Overall, the DGAs and ADA recommendations are largely concordant regarding foods to limit or avoid. The ADA's Standards of Care [&lt;span&gt;2&lt;/span&gt;] similarly recommend limiting intake of foods high in saturated fat to reduce cardiovascular disease risk. However, some differences remain; for example, while non-nutritive sweeteners are discouraged in the DGAs, they remain an option to replace added sugars in diabetes management by the ADA.&lt;/p&gt;&lt;p&gt;The National Health and Nutrition Examination Survey data show that ultra-processed food consumption increased from 2001–02 to 2017–18 among adults with prediabetes and diabetes; the proportion consuming ≥ 75% of daily calories from ultra-processed foods substantially increased from 12.4% to 21.4% in adults with ","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13171249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147925001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148075396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Impact of Revising the Diagnostic Criteria for Gestational Diabetes on Maternal Pregnancy and Infant Perinatal Outcomes","authors":"Qiliang Liu,&nbsp;Jane E. Harding,&nbsp;Greg D. Gamble,&nbsp;Carl Eagleton,&nbsp;Lisa Dawes,&nbsp;Caroline A. Crowther","doi":"10.1111/1753-0407.70232","DOIUrl":"10.1111/1753-0407.70232","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The revised diagnostic criteria for gestational diabetes (GDM) in New Zealand include lowering the fasting glucose from the current ≥ 5.5 to ≥ 5.3 mmol/L and replacing the current 2-h post-load glucose (≥ 9.0 mmol/L) with a 1-h glucose (≥ 10.6 mmol/L). We assessed the effects of these changes on the demographics of those diagnosed and their perinatal outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Participants in the GEMS trial were grouped as meeting only the revised criteria (Additional group), only the current criteria (Missed group), both criteria (Both-Criteria group), and neither criteria (Non-GDM group).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>GDM prevalence among 3921 participants was 6.8% using the revised criteria and 5.8% using the current criteria (risk ratio 1.18, 95% CI 1.00–1.40). Women in the Additional (<i>n</i> = 125) and Missed groups (<i>n</i> = 83), who would be affected by the changes, were more likely to be overweight/obese, have a family history of diabetes, and have Asian ethnicity than women in the Non-GDM group (<i>n</i> = 3562). They also had less gestational weight gain and more induced labors, while their infants were born earlier, had lower birthweight, and more neonatal hypoglycemia (all <i>p</i> &lt; 0.001). Women in the Missed group had lower BMI and fewer were of Pacific ethnicity than the Both-Criteria group (<i>n</i> = 151). They also had less pharmacotherapy use and postpartum hemorrhage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Using the revised criteria will increase GDM diagnoses by identifying a high-risk group of women likely to benefit from treatment, but 35.5% of women currently treated for GDM will no longer be diagnosed, potentially compromising their health.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13168750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147925021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148069943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Cardiometabolic Risk Markers on the Incidence and Progression Arterial Stiffness in Patients With Prediabetes","authors":"Qi Sun,&nbsp;Qiujing Cai,&nbsp;Yilin Huang,&nbsp;Shuyu Wang,&nbsp;Lisheng Liu,&nbsp;Zhiguang Liu,&nbsp;Aihua Hu,&nbsp;Wei Li,&nbsp;Biyan Wang","doi":"10.1111/1753-0407.70231","DOIUrl":"10.1111/1753-0407.70231","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Previous studies have reported that insulin resistance (IR), blood pressure, body mass index (BMI), and dyslipidemia are associated with arterial stiffness. However, limited evidence exists regarding these relationships in prediabetes patients. The purpose of this study was to investigate the longitudinal associations between cardiometabolic risk markers and progression of arterial stiffness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study included 5771 adults with prediabetes at baseline from the Shougang cohort study. Cardiometabolic risk markers included the triglyceride glucose (TyG) index, triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio, mean arterial pressure (MAP), BMI, and dyslipidemia. Arterial stiffness was assessed using brachial-ankle pulse wave velocity (baPWV), and its progression was defined as the annual change in baPWV between baseline and the last visit. Multivariate linear and logistic regression models were used to investigate the associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Multivariate linear regression analyses showed TyG index, TG/HDL-C ratio, MAP, and dyslipidemia were significantly associated with baseline baPWV. Over a mean follow-up of 3.24 years, each one-unit increase in the MAP was significantly associated with a faster progression of baPWV (difference, 0.72 cm/s per year; 95% CI, 0.40 to 1.04 cm/s per year). After adjusting for all covariates, the risk for arterial stiffness increased 3% with each one-unit increase of MAP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Among individuals with prediabetes, MAP showed consistent longitudinal associations with arterial stiffness, highlighting the importance of early blood pressure management for vascular protection prior to the onset of diabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"18 5","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13156238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147855787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}